Tissue Plasminogen Activator Market by Global Size, Trends, Revenue, 2019 Competitive Landscape, Reviews, Pricing Strategies, Key News by CMI
Tissue plasminogen activator (tPA) is an enzyme, which aids in the disintegration of blood clots. It is a serine protease present in endothelial cells. With the help of serine protease, the conversion of plasminogen to plasmin is catalyzed. Thus, serine protease is a major enzyme for clot disintegration.
Tissue plasminogen activator is produced by using a specific recombinant technology, known as recombinant tissue plasminogen activator (rtPA). Specific rtPAs consist of tenecteplase, alteplase, and reteplase. These enzymes are used in clinical treatment of thrombotic stroke or embolic stroke. tPA is a drug that helps dissolve blood clots, and is a major thrombolytic agent that can be administrated into the veins.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/2469
Global Tissue Plasminogen Activator Market – Drivers & Restraints
Tissue plasminogen activator is the first and only drug approved by the FDA in 1996 for the treatment of acute ischemic stroke. Increasing incidence of stroke has bolstered the global tissue plasminogen activator market expansion. As reported by John Hopkins Medicines (JHM), U.S., around 795,000 people in the U.S. suffer from stroke each year. According to the World Health Organization (WHO), stroke is the second leading cause of death and the third leading cause of disability, worldwide, as reported in 2012. This is one of the major factors driving the global market growth.
Surging prevalence of stroke incidences in growing geriatric population is another major factor driving the market size. As per the Public Health England (PHE), around 38% of people suffering from strokes were aged 40 to 69 in 2018. Moreover, tissue plasminogen activator market revenue is witnessing further increase due to awareness about stroke and its symptoms. In 2015, the Centers of Disease Control and Prevention (CDC) stated that around 38% of people were able to recognize the major symptoms of stroke and were treated at the right time.
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2469
On the contrary, various side effects of the drug, such as nausea, vomiting, dizziness, and fever, is a significant factor hindering the global tissue plasminogen activator market growth. Major side effects include hypertension, intracranial hemorrhage, systemic hemorrhage, angioedema, and others. tPA also leads to complications in the left ventricle. In 2011, the National Center for Biotechnology Information recorded around 2% to 5% of patients with acute ischemic stroke receive rtPA in the U.S. In 2015, CDC reported around 140,000 deaths due to unavailability and adverse effects of tPA in the U.S. Moreover, the global tissue plasminogen activator market growth can be hampered by substitute product approvals by the Food and Drug Administration (FDA). For instance, after the approval of stent retriever by FDA, in 2012, the global tissue plasminogen activator market growth was affected, since tPA is not effective for major blood clots, in comparison to the stent retriever thrombectomy.
Global Tissue Plasminogen Activator Market – Regional Analysis
North America is regarded as the frontrunner in the global tissue plasminogen activator market, in terms of market value, owing to the rising awareness about stroke in the region, coupled with huge spending on its treatment. For instance, in 2017, the American Heart Association (AHA) recorded stroke costs as US$ 34 billion in the U.S. every year, which includes medicines for the treatment of stroke and cost of health care services.
Asia pacific is the fastest-growing region in the tissue plasminogen activator market, owing to increasing demand drug coupled with rising stroke incidences in the region. According to WHO, Indonesia, Philippines, China, and India have highest rates of stroke, which is 186.3, 134.7, 128, and 71.5, respectively, as recorded in 2017.
The key players operating in the global tissue plasminogen activator market include Bayer AG, Abcam, Calbiochem, Merck & Company, Roche, Sekisui Diagnostics, Genentech, Sigma-Aldrich, Taj Pharmaceuticals, and Cadila Healthcare Ltd.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2469
By Route of Administration,
- Regional intra-arterial
- Blood clots
- Pulmonary embolism
- Myocardial infarction
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire